Proposed candidate materials and results of the feasibility studies for a WHO serological reference panel T.cruzi type II Márcia Otani Fundação Pró-Sangue.

Slides:



Advertisements
Similar presentations
Field evaluation of a rapid immunochromatographic assay for detection of Trypanosoma cruzi infection by use of whole blood 1. Médecins Sans Frontières.
Advertisements

TESTS USED IN BLOOD SCREENING French Blood Services (EFS)
Chagas Tests: Development and Standardization
Amadeo Sáez-Alquézar Second WHO Consultation: Development of a WHO reference panel for the control of Chagas diagnostic tests Geneva Development.
CHAGAS DISEASE Overwiev Diagnosis Proposals for WHO Ref.Preparation Alejandro O. Luquetti Laboratório de Pesquisa em Doença de Chagas Hospital das Clínicas.
Preparation, characterization and establishment of a WHO International Biological Reference Preparation Dr Sjoerd Rijpkema Division of Bacteriology NIBSC.
CBER Chagas Serological Lot Release Panel Development
Standardization of PCR for Trypanosoma cruzi detection
Assuring the Quality of Samples for Proficiency Testing or External Quality Assessment Schemes Terminology External quality assessment is a method for.
CHAGAS DISEASE Serological Diagnosis and the humoral immune response after specific treatment Alejandro O. Luquetti & Anis Rassi Laboratório de Pesquisa.
Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
To evaluate sensitivity, each of the 76 specimens (38 serum pairs) were tested using three serology tests. All testing was performed at the university.
Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
WHO comparative evaluation of serologic assays for Chagas disease Journal Club April 2, 2009.
The HIV Situation in the Philippines
6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.
Chagas Disease Tabitha Martel Epidemiology November 15, 2007.
Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,
Evaluation of Rapid Screening Methods for Emergency Blood Collections CPT Robert.
CHAGAS DISEASE Lucy Shearer. Carlos Chagas discovered the disease in 1909 © Oswaldo Cruz House - Fiocruz.
OnSite HAV IgM Rapid Test Upgraded to Revision H for Better Sensitivity CTK-MK-PPT-R0090 Rev 1.0.
Chagas Disease in the United States FDA BPAC meeting, 1 April 2009 Susan P. Montgomery, DVM MPH LCDR, USPHS Parasitic Diseases Branch Centers for Disease.
1 LABNET CURRENT HIV TESTING ACTIVITIES IN PACIFIC JURISDICTIONS.
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
Prof. Musabaev E.I. Quality Control Systems for Hepatitis B and C diagnostics in Uzbekistan.
And the order changeth …. Evolving protocols for TTI testing
HTLV-1 Associated Myelopathy Diagnosis and Treatment
Comparison of the diagnostic value of STA test and ELISA IgG and IgM in patients with Brucellosis Mustafa Ertek, Halil Yzgi, Zulal Ozkart et al. Turk.
Detection of Dengue Virus RNA in Blood Donors from Honduras and Brazil with a Prototype Transcription-Mediated Amplification Assay.
Trypanosoma cruzi. Endemic to Mexico, South America and Central America, infecting 8-11 million people there It is associated with poverty and poor housing.
T. cruzi Incidence Study in Blood Donors and its Implications for One-time Testing of Blood Donors Robert Duncan, Ph.D. DETTD, CBER, FDA Blood Products.
Prevalence of Hepatitis B infection in married women of child bearing age in District Islamabad Dr. Najma Javeed Awan Senior Medical Officer Pakistan Medical.
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
A preliminary report on the Leukocyte Antibody Prevalence Study (LAPS-I) Retrovirus Epidemiology Donor Study-II (REDS-II) presented by Dr. Steven Kleinman.
Standardisation of P. falciparum HBV, HCV and NAT Sally Baylis, NIBSC SoGAT XVIII.
1 Blood Systems Trypanosoma cruzi and Chagas Disease Studies and Potential Strategies for Targeted Testing of Donors Blood Products Advisory Committee.
Chagas Testing Icky things that can drop on you from your thatched roof! ABC 7-04.
1 Emerging Disease Surveillance and Response (ESR) WHO Western Pacific Regional Office (WPRO) Introduction to Group Work 1 Quality Assurance Programmes.
Comparison of the diagnostic value of STA test and ELISA IgG and IgM in patients with Brucellosis Mustafa Ertek, Halil Yzgi, Zulal Ozkart et al. Turk J.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.
Household Infestation Rates of Chagas Disease Vectors and Trypanosoma cruzi Prevalence in Southern Ecuador Stanton Jasicki Dr. Daniel Herman Dr. Mario.
Evaluation of the Presage™ ST2 ELISA Jun Lu 1, David G. Grenache 1,2 1 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 2 Department.
Issues Related to Implementation of Blood Donor Screening for Infection with Trypanosoma cruzi Presentation to BPAC April 26, 2007 Robert Duncan, PhD.
Update Rapid HIV Test Approval Requirements and Standards BPAC September 15, 2000 Kimber Poffenberger, Ph.D.
Panbio Dengue Duo Cassette
Dr. Gamaliel Gutiérrez Regional Dengue Program PAHO/WHO WDC
PROPOSED CANDIDATE MATERIAL FOR A WHO PANEL FOR SEROLOGICAL REFERENCE RESULTS OF THE FEASIBILITY STUDIES WITH SERA FROM TC I REGION RESULTS OF THE FEASIBILITY.
January 27, Paul Contestable Principal Scientist Ortho Clinical Diagnostics Second WHO Consultation: Development of a WHO Reference Panel for the.
Public health impacts of donor screening for T. cruzi infection Susan P. Montgomery, DVM MPH Division of Parasitic Diseases Centers for Disease Control.
Blood Products Advisory Committee Meeting April 26, 2007 Ben Marchlewicz, Ph.D. PRISM R&D, Program Manager.
Estimating Frequency of Travel to Endemic Areas Brian Custer, PhD, MPH Blood Systems Research Institute Blood Products Advisory Committee Meeting August.
Aaron Manning. Overview Also called American trypanosomiasis and the Kiss of Death A tropical parasitic disease caused by the flagellate protozoan Trypanosoma.
1 Update on Study to Further Define the Incidence of T. cruzi Infection in the US Blood Donor Population Susan L. Stramer, PhD American Red Cross BPAC.
Preventing Transmission of Chagas Disease in the U.S. Blood Supply: A Cost Effectiveness Analysis of Testing the Blood Bank Donations Danielle Doughman.
RETROVIRIDAE GENUS: ONCOVIRUS: HTLV-1 and HTLV-2 SPUMAVIRUS LENTIVIRUS: HIV-1 and HIV-2.
Screen Tests and Two By Two Tables Secondary Screen Tests for Disease and Methods to Check for Validity of These Tests A Flipped Classroom Presentation.
Geographical pattern of Q fever in Danish dairy cattle farms An epidemiological study of serological data from 2007 Material and methods Until 2003 antibodies.
TUPEB018 Field evaluation of rapid HIV serologic tests for screening HIV-1/2 infection using serum samples from Rakai Cohort, Uganda. S.C. Kagulire, P.D.
Screening for Trypanosoma cruzi antibodies and Strongyloides stercoralis antibodies in migrants to Italy coming from endemic areas using four immunological.
FIRST YEAR PHD SYMPOSIUM
Copyright © 2017 American Academy of Pediatrics.
Longitudinal Quality Assurance of HIV Nucleic Acid Testing in Blood Screening D Jardine, S Best, EM Dax (National Serology Reference Laboratory, Australia)
The RD1-encoded antigen Rv3872 of Mycobacterium tuberculosis as a potential candidate for serodiagnosis of tuberculosis  P. Mukherjee, M. Dutta, P. Datta,
History of Zika Virus 1947 New viral infection identified in the Zika Forrest, Uganda (research to id new viruses funded by the Rockefeller). This virus.
CHAGAS DISEASE.
RESEARCH ON THE PRODUCTION OF HBsAg STANDARD SERUM FOR QUALITY CONTROL
H. Leblebicioglu, C. Eroglu  Clinical Microbiology and Infection 
Newborn screening is a type of population screening to detect rare and serious conditions that can be easily and hastily treated before serious symptoms.
Volume 55, Issue 3, Pages (March 1999)
Presentation transcript:

Proposed candidate materials and results of the feasibility studies for a WHO serological reference panel T.cruzi type II Márcia Otani Fundação Pró-Sangue Hemocentro de São Paulo

Raw material Epidemiological data IDAgeGenderStateCollected date Plasma volume Female Minas Gerais Januaria, for 28 years MaleChile Canela, FemalePernambuco Buique, for 40 years MaleHidalgo, M é xico MaleHidalgo, M é xico

y 5 3

123 1-Have you ever heard about Chagas Disease? YYY 2-Do you know how to recognize a kissing bug? YYY 3-Have you ever lived in a house constructed of wood and mud? NNY 4-Have you had contact with a kissing bug? NYY 5-Have any of your relatives ever had Chagas disease? YNY 6-Did you live in the same house with a relative who is positive for Chagas Disease? NNY 7-Do you know any case of Chagas Disease in the region where you have born or where you have lived? NYY 8-Have you ever received blood transfusion? NNN 9-Have you ever been to any Chagas endemic region? NNN 10-Have you ever had any clinical symptoms for Chagas Disease ? NNY 11-Are you under medical treatment ? NNY 12-Have you ever done an electrocardiogram (EKG)? YYY Epidemiological Questionnaire

Raw material - Reactivity ID Elisa cruzi OD/CO Chagatek OD/CO Bioschile OD/CO Imuno cruzi Titre Used volume ml 9.36 Epd: 1/ Epd: 1/ Epd: 1/128 1/16080 ml ml 8.31 Epd: 1/ Epd: 1/ Epd: 1/128 1/ ml ml 7.97 Epd: 1/ Epd: 1/ Epd: 1/64 1/16060 ml ml 4.71 Epd: 1/ Epd: 1/ Epd: 1/32 1/1602 ml ml 5.37 Epd: 1/ Epd: 1/ Epd: 1/128 1/3202 ml Prototype = 260ml of positive ml of negative plasma from 7 donors units. (4.8 times diluted.) Epd = end point dilution (OD/CO) > 1

Raw material - serial dilution OD/CO ratio = Prototype = M2

Clinical Sensitivity and Specificity

Elisa cruziChagatekBioschileIFI Pure4,9625,4063,143 1/80 1/24,7924,7743,042 1/40 1/44,6773,6192,803 1/20 1/83,7582,7032,287Negative 1/162,6121,9102,020Negative 1/321,896 1,297 1,616Negative 1/64 1,362 0,8651,309Negative 1/1280,9230,542 1,046 Negative 1/2560,5810,4770,768Negative 1/5120,4350,4130,579Negative M2 OD/CO ratio

Prototype

Evaluating the Prototype EQAS to evaluate performance in loco. Send 1.8ml of the prototype serum to 25 reference centers in 16 countries in LA. Included 4 other non diluted not pooled samples to the same panel. Sep 2007 (OPS0207), Apr 2008 (OPS0108) and Sep 2008 (OPS0208).

Data from Latin America Reference Centers – PAHO Regional EQAS Cut off

Data from Latin America Reference Centers – PAHO Regional EQAS Sep 2007 Apr 2008 Sep 2008

Data from Latin America Reference Centers – PAHO Regional EQAS Sep 2007 Apr 2008 Sep 2008

Data from Latin America Reference Centers – PAHO Regional EQAS Sep 07 Apr 2008 Sep 08

Data from Latin America Reference Centers – PAHO Regional EQAS

Data from Latin America Reference Centers PAHO Regional EQAS

Prototype volume available = 1.4 liters 2 times dilution = 2.8 liters It is possible to obtain a total of 6 liters Unitsused mL available mL Volume Mexico Units M2 volume available = 400 mL 4 times dilution = 1.6 liters

Conclusion The mixture of 3 positive samples (from south of Latin America) diluted 4.8 times in negative samples have produced a prototype that presented stability at –20 ºC. We need to define the reactivity of the cut off value. Here we have used the dilution that is IIF = 1/20. Reactivity of the prototype diluted 2 times were 2 to 4 times de cutoff value in most of the tests evaluated and the IIF = 1/20. Perhaps we should submit this prototype to RIPA, Western Blot and Abbott Immunoassay.

Data from Latin America Reference Centers PAHO Regional EQAS